(Q46694127)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24861559%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

title

A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24861559%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24861559%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Marianne Koritzinsky

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24861559%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Ute Hofmann

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24861559%20AND%20SRC:MED&resulttype=core&format=json

Theodorus H Van der Kwast

19 March 2020

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24861559%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Joan Sweet

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24861559%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

author name string

V E Zannella

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24861559%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

M R Downes

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24861559%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

B Bowes

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24861559%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

K Hersey

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24861559%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

M Schwab

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24861559%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

A Evans

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24861559%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

J Trachtenberg

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24861559%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

A Finelli

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24861559%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

N Fleshner

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24861559%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

M Pollak

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24861559%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

publication date

27 May 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24861559%20AND%20SRC:MED&resulttype=core&format=json

Prostate Cancer and Prostatic Diseases

19 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24861559%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24861559%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

page(s)

252-258

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24861559%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24861559%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/pcan.2014.20

19 March 2020

exact match

0 references

cites work

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2014.20

Insulin-lowering effects of metformin in women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2014.20

Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2014.20

Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2014.20

Insulin receptor expression by human prostate cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2014.20

Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2014.20

Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2014.20

Association between metformin use and risk of prostate cancer and its grade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2014.20

Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2014.20

Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2014.20

Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2014.20

Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2014.20

Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2014.20

Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2014.20

Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2014.20

Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2014.20

Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2014.20

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2014.20

Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2014.20

Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2014.20

Oct1 regulates cell growth of LNCaP cells and is a prognostic factor for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2014.20

Towards a knowledge-based Human Protein Atlas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2014.20

Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on Radiation Therapy Oncology Group (RTOG) 94-08.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2014.20

Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2014.20

Increased serum insulin associated with increased risk of prostate cancer recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2014.20

Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2014.20

Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2014.20